UY29740A1 - Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol - Google Patents
Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamolInfo
- Publication number
- UY29740A1 UY29740A1 UY29740A UY29740A UY29740A1 UY 29740 A1 UY29740 A1 UY 29740A1 UY 29740 A UY29740 A UY 29740A UY 29740 A UY29740 A UY 29740A UY 29740 A1 UY29740 A1 UY 29740A1
- Authority
- UY
- Uruguay
- Prior art keywords
- salbutamol
- formulations
- hfc
- citrate
- hydrochloride
- Prior art date
Links
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960002052 salbutamol Drugs 0.000 title abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 2
- OWNWYCOLFIFTLK-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;hydron;chloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 OWNWYCOLFIFTLK-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulaciones de disolución para aerolol estabilizadas que contienen sales de edicinon de ácido de salbutamol, adecuadas para sua administración poe inhaladores de dosis medidas (los MDI).Formulaciones de una disolición que contiene un a de la sales mencionadas anteriormente de salburamol, preferiblemente hidroclururo de dalbutamolo citrato de salbutamol, más preferiblemente una de dicha sales en combinación con una o más sustancias farmacológicamente activas adicionales, junto con un hidrofluorocabono (HFC) medioambientalmente seguro como propelente, un disolvente conjunto, preferiblemente un compuesto orgánico como disolvente conjunto y bién un ácido inorgánico o un ácido orgánoco.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05017599 | 2005-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29740A1 true UY29740A1 (es) | 2007-03-30 |
Family
ID=35564491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29740A UY29740A1 (es) | 2005-08-12 | 2006-08-11 | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070041911A1 (es) |
AR (1) | AR057745A1 (es) |
PE (1) | PE20070353A1 (es) |
TW (1) | TW200800141A (es) |
UY (1) | UY29740A1 (es) |
WO (1) | WO2007020204A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
ES2866175T3 (es) | 2015-12-04 | 2021-10-19 | Mexichem Fluor Sa De Cv | Composición farmacéutica |
MY202069A (en) | 2016-09-19 | 2024-03-31 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
US11260052B2 (en) | 2016-09-19 | 2022-03-01 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
EP3515425B1 (en) | 2016-09-19 | 2021-06-09 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising salmeterol |
JOP20200314A1 (ar) * | 2018-06-04 | 2020-12-06 | Lupin Inc | تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة |
FR3130554A1 (fr) | 2021-12-20 | 2023-06-23 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
EP1736147A3 (en) * | 1991-06-10 | 2007-10-17 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
JP2003221335A (ja) * | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
CN1216600C (zh) * | 2002-04-24 | 2005-08-31 | 信谊药厂 | 盐酸左旋沙丁胺醇气雾剂及制备工艺 |
CN1228045C (zh) * | 2003-11-03 | 2005-11-23 | 王立强 | 口腔速崩速溶片制剂及其制备方法 |
GB0406069D0 (en) * | 2004-03-17 | 2004-04-21 | Thompson James | Process |
-
2006
- 2006-08-04 WO PCT/EP2006/065090 patent/WO2007020204A2/en active Application Filing
- 2006-08-09 US US11/463,477 patent/US20070041911A1/en not_active Abandoned
- 2006-08-10 PE PE2006000973A patent/PE20070353A1/es not_active Application Discontinuation
- 2006-08-11 TW TW095129480A patent/TW200800141A/zh unknown
- 2006-08-11 AR ARP060103518A patent/AR057745A1/es not_active Application Discontinuation
- 2006-08-11 UY UY29740A patent/UY29740A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20070353A1 (es) | 2007-04-19 |
TW200800141A (en) | 2008-01-01 |
AR057745A1 (es) | 2007-12-12 |
WO2007020204A3 (en) | 2007-06-07 |
US20070041911A1 (en) | 2007-02-22 |
WO2007020204A2 (en) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29740A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
DK1257254T3 (da) | Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom | |
AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
ECSP088403A (es) | Formulacion farmaceutica de absorción oral y su método de administracion | |
MXPA06011467A (es) | Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid). | |
ATE471144T1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
ECSP045238A (es) | Forma de dosis oral que contiene un inhibidor de pde 4 como un ingrediente activo y polivinilpirrolidona como excipiente | |
ATE341309T1 (de) | Pulmonale arzneistoffverabreichung | |
UY30265A1 (es) | Inhalador | |
ECSP077368A (es) | Mecanismo de visualización de dosis para un dispositivo para la administración de fármacos | |
WO2006044421A3 (en) | Cardiac safe, rapid medication delivery | |
NO20080827L (no) | Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon | |
CO6382132A2 (es) | Tratamiento de pirfenidona para pacientes con funcion hepatica atipica | |
NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
BRPI0507225A2 (pt) | formulações estáveis de solução farmacêutica para inaladores pressurizados de dose medida | |
AR059359A1 (es) | Formulaciones farmaceuticas que contienen pleconaril | |
DK2089008T3 (da) | Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator | |
NO20074854L (no) | Farmasoytiske aerosolformuleringer for komprimerte, utmalte doseinhalatorer omfattende et sekvestreringsmiddel | |
WO2007009691A3 (en) | Combination of substituted pyrazolines and anti -addictive agent | |
ECSP109871A (es) | Soluciones farmacéuticas orales que contienen telbivudina | |
WO2005097192A3 (en) | Active substance combination of a carbinol compound and an opioid | |
CR9577A (es) | Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil) | |
WO2005065682A3 (en) | Rabeprazole containing formulation | |
CR9563A (es) | Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] no micromizado, y sus sales | |
AR094287A1 (es) | Metodos y composiciones para administracion de oxibutinina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20160830 |